August 8th 2025
The 2025 National ICE-T Symposium gave oncology experts an opportunity to share ideas regarding the administration of cellular therapies.
Investigators report a case of a man, aged 55 years, with an extensive and prolonged course of an unexplained multi-systemic disease, and also review common clinical manifestations, mutations, diagnoses, and targeted therapies for Erdheim-Chester disease.
CMV reactivation and disease progression in response to different GVHD prophylaxis methods
July 25th 2023The difference in utilizing cytomegalovirus reactivation outcomes while on posttransplantation cyclophosphamide vs other graft-vs-hose disease agents has led to a better understanding in long-term disease and reinfection rates.
FDA Approves Ready-to-Dilute Cyclophosphamide Injection NDA in Blood Cancers
July 10th 2023Patients with select hematologic cancers, including lymphoma and multiple myeloma, appear to benefit from a ready-to-dilute formation of intravenous cyclophosphamide, the new drug application for which was approved by the FDA.
Palliative Care in HSCT Correlates With Longer Survival in Hematologic Cancers
June 14th 2023A retrospective analysis of more than 17,000 patients with hematologic malignancies identified a difference in median survival between patients who received palliative care in addition to hematopoietic stem cell transplantation and those who didn’t.
Ruxolitinib Appears to Yields Superior Responses in Polycythemia Vera Subtype
May 18th 2023Findings from the phase 2 MAJIC-PV trial highlight a superior event-free survival and overall survival following ruxolitinib vs best available treatment in patients with polycythemia vera who were intolerant/resistant to hydroxycarbamide.
FDA Accepts Supplemental NDA for Avapritinib in Indolent Systemic Mastocytosis
January 24th 2023Data from the phase 2 PIONEER trial supports the supplemental new drug application for avapritinib in adult patients with indolent systemic mastocytosis, an uncontrolled proliferation and activation of mast cells.